Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL

12 Jul 2022

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) typically presents as metastatic disease at diagnosis and remains refractory to treatment. Next-generation sequencing efforts have described the genomic landscape, classified molecular subtypes, and confirmed frequent alterations in major driver genes, with coexistent alterations in KRAS and TP53 correlating with the highest metastatic burden and poorest outcomes. However,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer-related Molecular Pathways
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35819261
DOI: 10.1158/0008-5472.can-21-4222

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAILPMID 35819261Read ↗

The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.Semantic proximity Read ↗

Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.Semantic proximity Read ↗

PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSemantic proximity Read ↗

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionSemantic proximity Read ↗

TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stressSemantic proximity Read ↗

Base-excision repair pathway regulates transcription-replication conflicts in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Base Excision Repair Pathway Regulates Transcription-Replication Conflicts in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.Semantic proximity Read ↗

KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survivalSemantic proximity Read ↗

CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.Semantic proximity Read ↗

TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethalitySemantic proximity Read ↗

Therapeutic Targeting of Oncogene-induced Transcription-Replication Conflicts in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.